Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P22301

UPID:
IL10_HUMAN

ALTERNATIVE NAMES:
Cytokine synthesis inhibitory factor

ALTERNATIVE UPACC:
P22301

BACKGROUND:
Interleukin-10, with its alternative name Cytokine Synthesis Inhibitory Factor, is a major immune regulatory cytokine. It exerts anti-inflammatory effects across the immune system, notably by inhibiting the release of pro-inflammatory cytokines from macrophages and monocytes, and dampening T cell activation. IL-10's interaction with its receptor activates a signaling pathway that reprograms cellular responses to inflammation, highlighting its critical role in immune regulation.

THERAPEUTIC SIGNIFICANCE:
The exploration of Interleukin-10's functions illuminates its potential as a therapeutic target. Given its central role in mitigating inflammation and regulating immune responses, strategies to harness IL-10's properties could lead to innovative treatments for managing chronic inflammatory and autoimmune conditions, offering new hope for patients.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.